Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2471-2475

  Peiper, Matthias ^a,b   Goedegebuure, Peter S ^b   Izbicki, Jakob R ^a   Eberlein, Timothy J ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CTL HER2 neu; Pancreatic cancer; Tumor associated antigen

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GP2 PEPTIDE; HLA A2 ANTIGEN; MEMBRANE PROTEIN; ONCOPROTEIN; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ASCITES; CANCER IMMUNOTHERAPY; CASE REPORT; CELL STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PANCREAS CANCER; PRIORITY JOURNAL; PROTO ONCOGENE; SEQUENCE HOMOLOGY; T LYMPHOCYTE; TUMOR CELL;

EID: 0032815539     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Topalian SL, Solomon D, Rosenberg SA: Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714-3725, 1989.
2. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ: Breast and ovarian cancer-specific cytotoxic T Lymphocytes recognize the same HER2/neu -derived peptide. Proc Natl Acad Sci USA 92: 432-436, 1995.
3. Traversari C, van der Bruggen P, Luescher IF, Lurqiun C, CHomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176: 1453-1457, 1992.
4. Kawakami Y, Eliyahu S, Sakaguchi K, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180: 347-352, 1994.
5. Wahab ZA, Metzgar RS: Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells. Pancreas 6: 307-317, 1993.
6. Wölfel T, Herr W, Coulie P, Schmitt U, Meyer zum Büschenfelde K-H, Knuth A: Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer 54: 636-644, 1993.
7. Katano M, Nagumo E, Kubota E, Yamamoto H, Matsuo T, Hisatsugu T, Tadano J: Autologous tumour-specific cytotoxic T-cell clone established from tumour-infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2 (rIL2): activation by autologous tumour cell alone. Biotherapy 6: 25-32, 1993.
8. Okada N, Ohshio G, Yamaki K, Imamura T, Imamura M: Elevated serum c-erbB2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. Oncology 52: 392-396, 1995.
9. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ: Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155: 4486-4491, 1995.
10. Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville C, Eberlein TJ: The HER2/neu derived peptide p654-662 is a TAA in human pancreatic cancer recognized by T lymphocytes. Eur J Immunol 27: 1115-1121, 1997.
11. Peoples GE, Schoof DD, Andrews VR, Goedegebuure PS, Eberlein TJ: T-cell recognition of ovarian cancer. Surgery 114: 227-234, 1993.
12. Schoof DD, Selleck CM, Massaro AF, Jung SE, Eberlein TJ: Activation of tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res 50: 1138-1143, 1990.
13. Fisk B, Savary C, Hudson JM, O'Brian CA, Murray JL, Wharton JT, Ioannides CG: Changes in an HER2/neu peptide upregulating HLA-A2 expression on both confirmational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. J Immunother 18: 197-209, 1995.
14. Peiper M, Goedegebuure PS, Eberlein TJ: Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable to lyse human pancreatic cancer cells. Surgery 122: 235-242, 1997.
15. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ: Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 194: 2393-2400, 1994.
16. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee H-G: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (London) 351: 290-296, 1991.
17. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A: Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74: 929-937, 1993.
18. Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R: Multivariate Analyse von Prognosefaktoren nach Resektion duktaler Pankreaskarzinome. Langenbecks Arch Chir 380: 133-138, 1995.
19. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ: HER2/neu-derived peptides are shared antigens among human non small cell lung cancer and ovarian cancer. Cancer Res 54: 3387-3390, 1994.
20. Magarian-Blander J, Domenech N, Finn OJ: Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA. Ann NY Acad Sci 690: 231-246, 1993.